Teligent’s Manufacturing and Research and Development Complex Expansion, Buena, New Jersey, United States of America


Teligent

Specialty generic pharmaceutical company Teligent broke ground for the expansion of its FDA-approved manufacturing, and research and development (R&D) complex in Buena, New Jersey, US, on 24 June 2016.

The company expects to become a leading player in the generic pharmaceutical products market by speeding up the launch of priority products. The expansion project is expected to deliver a high-quality facility that will increase Teligent's production capacity of topical, injectable, complex and ophthalmic generic pharmaceutical products.

Construction on the facility is expected to be completed by 2017.

Teligent's manufacturing and R&D complex details

The existing facility is spread across an area of 23,000ft² (2,136.8m²) and contains space for laboratories, a warehouse, and a topical pharmaceutical manufacturing and packaging unit. It is capable of producing both pharmaceuticals and medical devices. It also produces creams, lotions, gels, solutions and suspensions.

Teligent recently acquired a 10,500ft² (975.4m²) building adjacent to the existing facility to develop an R&D laboratory and administrative offices. The new building is being renovated and is expected to be operational in 2016.

Details of Teligent's expansion project in Buena

The expansion project, estimated to cost between $45m and $50m, will add 75,000ft² (6,967.8m²) to the existing complex to increase the total floor space by approximately 300% to 110,000ft² (10,219.3m²). It will add a number of topical compounding rooms and packaging lines including a new high-speed bottle filler.

A new sterile injectable manufacturing suite will also be installed as part of the project. The new unit will be fitted with an isolator-based fill line for vials and ampoules. The project also includes the construction of a compounding room for production of alcohol-based products. Improved quality control laboratories and a highly efficient warehouse will also be added.

Regional economic impacts of Teligent's expansion project

The project is expected to generate $78m in new economic activity in the southern New Jersey region, and 454 temporary jobs during the construction phase.

"The expansion project is expected to deliver a high-quality facility that will increase Teligent's production capacity."

By 2018, the project is expected to increase regional employment by 67% and generate $21.4m in annual earnings for the regional workers. It will also provide 200 jobs for skilled and entry-level positions within the company in R&D, manufacturing and administration.

Marketing commentary

Teligent develops, manufactures and markets generic pharmaceutical products for US and Canada. The existing market consolidation between generic and branded markets provides sizable opportunities for Teligent's growth. The generics market in the US alone is expected to grow at 16% over the next three years, providing significant opportunities for Teligent.

The company has been increasing its focus towards the growing topical, injectable, complex and ophthalmic generics markets in these regions. With this focus, the company acquired Alveda Pharmaceuticals in 2015 to expand its specialty generic pharmaceutical portfolio across Canada.

The Buena facility expansion will help Teligent in leveraging its R&D, regulatory, quality and commercial infrastructure to supply a broader mix of generic pharmaceutical products to the market. It will also help in establishing a robust cycle of lab-to-CMO transfers and commercially develop its product portfolio.